Presenter Dr. Tone Hovda of Vestre Viken Hospital Trust in Drammen will share results from a study conducted with Solveig Hofvind, PhD, head of the Norwegian Breast Cancer Screening Program. The two compared rates of interval breast cancer among women screened with DBT in combination with synthesized 2D mammography and those screened with standard digital mammography.
The study included 94,075 women screened between 2014 and 2015. Of these, 35,303 were screened with DBT plus synthesized 2D mammography and 58,772 with digital mammography. Women included in the study were followed for interval breast cancer two years after their initial screening exam. The rates of screen-detected breast cancer were 9.4 per 1,000 exams in the DBT group and 6.1 per 1,000 exams in the digital mammography group.
The researchers found no statistically significant interval breast cancer rates between the DBT group (2 per 1,000 exams) and the digital mammography group (1.5 per 1,000 exams).
"Despite of a higher rate of screen-detected breast cancer among women screened with DBT compared with digital mammography, we observed no statistical significant differences in rates or histopathological tumor characteristics of interval breast cancer between the groups," they concluded.